Initial data from a first-in-human trial of RG7116 have shown that downregulation of membrane HER3 is also seen in skin samples of patients with HER3-positive epithelial tumors treated with RG7116 (at a dose of 100 mg and above), and this was associated with downregulation of HER3 in on-treatment tumor samples (at 200 mg and above) [30]. This evidence concerns the gene ERBB3 and neoplasm.